IP Library › Granted Patent US 10,308,708
Granted Patent B2
US 10,308,708 · App. 15/238,419 · Granted Jun 4, 2019

Antibodies that neutralize botulinum neurotoxins

Inventors: James D. Marks (Kensington, CA); Isin N. Geren (San Francisco, CA)
Assignee: The Regents of the University of California
C07K16/1282A61K2039/505A61K2039/507C07K2317/21C07K2317/52C07K2317/54C07K2317/55C07K2317/565C07K2317/622C07K2317/76C07K2317/92C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,708
App. No.
15/238,419
Granted
Jun 4, 2019
Kind
B2
Abstract

This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Claims (104)

1. A composition comprising:

a first nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable heavy chain (V H ) polypeptide comprising

a V H CDR1 comprising the amino acid sequence of HYGMH (SEQ ID NO:492);

a V H CDR2 comprising the amino acid sequence of VIWYDGRNPYYAASVKG (SEQ ID NO:494); and

a V H CDR3 comprising the amino acid sequence of DLTRFHDTTFGVFEM (SEQ ID NO:496); and

a second nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable light chain (V L ) polypeptide comprising

a V L CDR1 comprising the amino acid sequence of RASQGISSWLA (SEQ ID NO:742);

a V L CDR2 comprising the amino acid sequence of AASSLQS (SEQ ID NO:744); and

a V L CDR3 comprising the amino acid sequence of QQYSSLYT (SEQ ID NO:746);

wherein the first and second isolated nucleic acids are on the same or different nucleic acid constructs.

2. A composition comprising:

a first nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable heavy chain (V H ) polypeptide comprising

a V H CDR1 comprising the amino acid sequence of GFTFSHYG (SEQ ID NO:1309);

a V H CDR2 comprising the amino acid sequence of IWYDGRNP (SEQ ID NO:1310);

and

a V H CDR3 comprising the amino acid sequence of VKDLTRFHDTTFGVFEM (SEQ ID NO:1311); and

a second nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable light chain (V L ) polypeptide comprising

a V L CDR1 comprising the amino acid sequence of QGISSW (SEQ ID NO:1312);

a V L CDR2 comprising the amino acid sequence of AAS (SEQ ID NO:1313); and

a V L CDR3 comprising the amino acid sequence of QQYSSL (SEQ ID NO:1314);

wherein the first and second isolated nucleic acids are on the same or different nucleic acid constructs.

3. A composition comprising:

a first nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable heavy chain (V H ) polypeptide comprising

a V H CDR1 comprising the amino acid sequence of HYGMH (SEQ ID NO:492);

a V H CDR2 comprising the amino acid sequence of VIWYDGRNPYYAASVKG (SEQ

ID NO:494); and

a V H CDR3 comprising the amino acid sequence of DLTRFHDTTFGVFEM (SEQ ID NO:496); and

a second nucleic acid comprising the isolated nucleic acid comprising a nucleotide sequence encoding a variable light chain (V L ) polypeptide comprising

a V L CDR1 comprising the amino acid sequence of RASQSISSWLA (SEQ ID NO:735);

a V L CDR2 comprising the amino acid sequence of KASSLEN (SEQ ID NO:737); and

a V L CDR3 comprising the amino acid sequence of QQYSTYSRT (SEQ ID NO:739);

wherein the first and second isolated nucleic acids are on the same or different nucleic acid constructs.

4. A composition comprising:

a first isolated nucleic acid comprising a nucleotide sequence encoding a variable heavy chain (V H ) polypeptide comprising the amino acid sequence of SEQ ID NO:19; and

a second isolated nucleic acid comprising a nucleotide sequence encoding a variable light chain (V L ) polypeptide comprising:

a V L CDR1 comprising the amino acid sequence of RASQGISSWLA (SEQ ID NO:742);

a V L CDR2 comprising the amino acid sequence of AASSLQS (SEQ ID NO:744); and

a V L CDR3 comprising the amino acid sequence of QQYSSLYT (SEQ ID NO:746); or

a V L CDR1 comprising the amino acid sequence of QGISSW (SEQ ID NO:1312);

a V L CDR2 comprising the amino acid sequence of AAS (SEQ ID NO:1313); and

a V L CDR3 comprising the amino acid sequence of QQYSSL (SEQ ID NO:1314); or

a V L CDR1 comprising the amino acid sequence of RASQSISSWLA (SEQ ID NO:735);

a V L CDR2 comprising the amino acid sequence of KASSLEN (SEQ ID NO:737); and

a V L CDR3 comprising the amino acid sequence of QQYSTYSRT (SEQ ID NO:739); or

the amino acid sequence of SEQ ID NO: 55; or

the amino acid sequence of SEQ ID NO: 54

wherein the first and second isolated nucleic acids are on the same or different nucleic acid constructs.

5. The composition of claim 4 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding a V L polypeptide comprising:

a V L CDR1 comprising the amino acid sequence of RASQGISSWLA (SEQ ID NO:742);

a V L CDR2 comprising the amino acid sequence of AASSLQS (SEQ ID NO:744); and

a V L CDR3 comprising the amino acid sequence of QQYSSLYT (SEQ ID NO:746).

6. The composition of claim 4 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding a V L polypeptide comprising:

a V L CDR1 comprising the amino acid sequence of QGISSW (SEQ ID NO:1312);

a V L CDR2 comprising the amino acid sequence of AAS (SEQ ID NO:1313); and

a V L CDR3 comprising the amino acid sequence of QQYSSL (SEQ ID NO:1314).

7. The composition of claim 4 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding a V L polypeptide comprising the amino acid sequence of SEQ ID NO: 55.

8. The composition of claim 4 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding a V L polypeptide comprising:

a V L CDR1 comprising the amino acid sequence of RASQSISSWLA (SEQ ID NO:735);

a V L CDR2 comprising the amino acid sequence of KASSLEN (SEQ ID NO:737); and

a V L CDR3 comprising the amino acid sequence of QQYSTYSRT (SEQ ID NO:739).

9. The composition of claim 4 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding a V L polypeptide comprising the amino acid sequence of SEQ ID NO: 54.

10. A composition comprising:

a first isolated nucleic acid comprising a nucleotide sequence encoding a V L polypeptide comprising the amino acid sequence of SEQ ID NO:55; and

a second isolated nucleic acid comprising a nucleotide sequence encoding a V H polypeptide comprising:

a V H CDR1 comprising the amino acid sequence of HYGMH (SEQ ID NO:492);

a V H CDR2 comprising the amino acid sequence of VIWYDGRNPYYAASVKG (SEQ ID NO:494);

a V H CDR3 comprising the amino acid sequence of DLTRFHDTTFGVFEM (SEQ ID NO:496); or

a second isolated nucleic acid present on a nucleic acid construct, the second isolated nucleic acid comprising a nucleotide sequence encoding a V H polypeptide comprising:

a V H CDR1 comprising the amino acid sequence of GFTFSHYG (SEQ ID NO:1309);

a V H CDR2 comprising the amino acid sequence of IWYDGRNP (SEQ ID NO:1310);

a V H CDR3 comprising the amino acid sequence of VKDLTRFHDTTFGVFEM (SEQ ID NO:1311);

wherein the first and second isolated nucleic acids are on the same or different constructs.

11. The composition of claim 10 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding an amino acid sequence of a V H polypeptide comprising:

a V H CDR1 comprising the amino acid sequence of HYGMH (SEQ ID NO:492);

a V H CDR2 comprising the amino acid sequence of VIWYDGRNPYYAASVKG (SEQ ID NO:494); and

a V H CDR3 comprising the amino acid sequence of DLTRFHDTTFGVFEM (SEQ ID NO:496).

12. The composition of claim 10 , wherein the second isolated nucleic acid comprises a nucleotide sequence encoding an amino acid sequence of a V H polypeptide comprising:

a V H CDR1 comprising the amino acid sequence of GFTFSHYG (SEQ ID NO:1309);

a V H CDR2 comprising the amino acid sequence of IWYDGRNP (SEQ ID NO:1310); and

a V H CDR3 comprising the amino acid sequence of VKDLTRFHDTTFGVFEM (SEQ ID NO:1311).

13. A nucleic acid construct comprising:

i) a first nucleic acid comprising a nucleotide sequence encoding an amino acid sequence of a variable heavy chain (V H ) polypeptide comprising

a V H CDR1 comprising the amino acid sequence of HYGMH (SEQ ID NO:492);

a V H CDR2 comprising the amino acid sequence of VIWYDGRNPYYAASVKG (SEQ ID NO:494); and

a V H CDR3 comprising the amino acid sequence of DLTRFHDTTFGVFEM (SEQ ID NO:496); or

a V H CDR1 comprising the amino acid sequence of GFTFSHYG (SEQ ID NO:1309);

a V H CDR2 comprising the amino acid sequence of IWYDGRNP (SEQ ID NO:1310); and

a V H CDR3 comprising the amino acid sequence of VKDLTRFHDTTFGVFEM (SEQ ID NO:1311); and

ii) a second nucleic acid comprising a nucleotide sequence encoding a variable light chain (V L ) polypeptide comprising:

a V L CDR1 comprising the amino acid sequence of RASQGISSWLA (SEQ ID NO:742);

a V L CDR2 comprising the amino acid sequence of AASSLQS (SEQ ID NO:744); and

a V L CDR3 comprising the amino acid sequence of QQYSSLYT (SEQ ID NO:746); or

a V L CDR1 comprising the amino acid sequence of QGISSW (SEQ ID NO:1312);

a V L CDR2 comprising the amino acid sequence of AAS (SEQ ID NO:1313); and

a V L CDR3 comprising the amino acid sequence of QQYSSL (SEQ ID NO:1314) or

a V L CDR1 comprising the amino acid sequence of RASQSISSWLA (SEQ ID NO:735);

a V L CDR2 comprising the amino acid sequence of KASSLEN (SEQ ID NO:737); and

a V L CDR3 comprising the amino acid sequence of QQYSTYSRT (SEQ ID NO:739).

14. A cell comprising the first and second isolated nucleic acids of claim 1 .

15. A cell comprising the first and second isolated nucleic acids of claim 2 .

16. A cell comprising the first and second isolated nucleic acids of claim 3 .

17. A method of making a polypeptide, the method comprising culturing the cell of claim 14 under conditions suitable for the cell to express the polypeptide, wherein the polypeptide is produced.

18. A method of making a polypeptide, the method comprising culturing the cell of claim 15 under conditions suitable for the cell to express the polypeptide, wherein the polypeptide is produced.

19. A method of making a polypeptide, the method comprising culturing the cell of claim 16 under conditions suitable for the cell to express the polypeptide, wherein the polypeptide is produced.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2016
From: MARKS, JAMES D.; LOU, JIANLONG; RODRIGUEZ, MARIA CONSUELO G.; GEREN, ISIN N.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 040727/0668 →
Continuity (4)
Division 14634355 · Feb 27, 2015
Division 13055436
Provisional Application 61085328 · Jul 31, 2008
Related Publication 20170096474A1 · Apr 6, 2017
Cited By (2)
US 12,441,813 US 12,448,463